Trinity Biotech plc (TRIB), a biotechnology company focused on diabetes management, on Thursday announced notable advances in its pre-pivotal trial for its next-generation continuous glucose monitoring or CGM system.
The findings show approximately 35 percent improvement in first-day accuracy or Mean Absolute Relative Difference or MARD and more than 50 percent improvement in Mean Absolute Difference or MAD compared to its previous Waveform product.
These advancements address a key issue in the CGM market—first-day sensor accuracy, which has historically fluctuated due to body responses.
The trial, involving 30 diabetic participants, also highlighted improvements in signal quality, sensor reliability, and low-glucose precision.
The new design of Trinity's CGM system aims to make continuous glucose monitoring more affordable, sustainable, and accessible, with a focus on reducing costs and environmental impact.
Trinity plans to submit regulatory filings in Europe in 2025, followed by a U.S. FDA filing in 2026, and further pre-pivotal trials are set to begin in Q1 2025.
TRIB closed Wednesday's (FEB.05 2025) trading at $0.86 down by 7.31%. In premarket trading Thursday the stock is down by 0.20% at $0.86.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.